ANTONIO CRAXI, M.D.; GATTO GIOVANNI, M.D.; ALBERTO MARINGHINI, M.D.; SALVATORE ORSINI, M.D.; GIOVANNI PINZELLO, M.D.; LUIGI PAGLIARO, M.D.
To the editor: Disopyramide (Norpace; G. D. Searle & Company, Chicago, Illinois) has been marketed in Europe since 1969 and has been widely accepted as an effective, well-tolerated antiarrhythmic agent. Cholestatic jaundice has been reported in at least three patients on disopyramide (1-3). Recently we have observed three more patients with cholestasis probably related to disopyramide. The relevant laboratory data are given in Table 1. The patients had no hepatosplenomegaly, fever, abdominal pain, or heart failure; tests for hepatitis B surface antigen, alpha-fetoprotein, and antimitochondrial antibodies were always negative.
Patient 1 was a 63-year-old man who received, after a myocardial
ANTONIO CRAXI, GATTO GIOVANNI, ALBERTO MARINGHINI, SALVATORE ORSINI, GIOVANNI PINZELLO, LUIGI PAGLIARO. Disopyramide and Cholestasis. Ann Intern Med. 1980;93:150–151. doi: 10.7326/0003-4819-93-1-150_2
Download citation file:
Published: Ann Intern Med. 1980;93(1_Part_1):150-151.
Biliary Disorders, Cardiology, Gastroenterology/Hepatology, Rhythm Disorders and Devices.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use